Committed to tackling conditions commonly associated with aging, Cellmid is leveraging innovative technologies against important targets for the development of consumer and pharmaceutical products.
To learn more about Cellmid’s Coronavirus tests please click HERE
Committed to tackling conditions commonly associated with aging, Cellmid is leveraging innovative technologies against important targets for the development of consumer and pharmaceutical products.
To learn more about Cellmid’s Coronavirus tests please click HERE
Focusing on growing shareholder value
Fast growing consumer business
Anti-aging functional cosmetics and consumer health products for hair, face and wellbeing.
High value drug development assets
Extensive intellectual property surrounding the novel target midkine, an important driver and modulator of inflammatory diseases
Corporate
information
Cellmid is an Australian Company listed on the Australian Stock exchange
ASX: CDY
Cellmid is developing first in class and best in class solutions to a range of conditions associated with aging. Cellmid’s consumer health division, Advangen Limited, develops, manufactures and markets innovative products for hair loss, thinning and hair aging with rapidly growing operations in Australia, Japan, the USA, Europe and Asia. Through its wholly owned subsidiary Lyramid Limited, Cellmid is developing treatments for inflammatory and autoimmune conditions.
Broker Insights
Get an in-depth profile of Cellmid Limited (CDY) share information by Small Cap Insider.
Cellmid in the media
Media coverage of Cellmid’s drug development and consumer health divisions